As a new-type foreign trade service provider driven by technological transformation and foreign trade services, HiSiaddi has established a service system of "1+2+3+4=1" and can supply PVP from multiple well-known original manufacturers. With over a decade of market experience and long-term factory technology transformation cooperation, HiSiaddi possesses extensive experience addressing product compliance issues. Below is a case study of HiSiaddi’s resolution of PVP cross-border compliance issues.
Contact HiSiaddi customer service for more inquiries on PVP product compliance issues.
SandoCare, a listed Swiss pharmaceutical group, distributes products to public hospital pharmacies across Switzerland, France and Luxembourg with extremely strict raw material access thresholds. After confirming supply from two major domestic PVP manufacturers and passing all formulation sample tests, four fatal compliance risks emerged shortly before shipment, threatening port detention and return of the entire order:
1. Incomplete REACH Compliance: Manufacturers only completed basic substance registration, lacking downstream usage registration for pharmaceutical excipients and annual update reports for SVHC Substances of Very High Concern. New EU customs regulations require pharmaceutical-grade PVP to include complete REACH Annex XVII solvent limit filings; missing documents result in direct cargo detention and inspection upon arrival.
2. Incomplete EU Raw Material Export Qualifications: Production factories lacked the official Certificate of Export API to the EU issued by China’s NMPA, failing to meet EU pharmaceutical authority requirements for audit of overseas pharmaceutical excipient suppliers. The client could not complete supplier filing with Swiss drug authorities, halting formulation registration.
3. Non-Compliant DMF & CEP Documentation: Manufacturers held simplified DMF dossiers but failed to update full risk assessment data for genotoxic impurities and NVP monomers per the latest FDA GDUFA standards. CEP certificates only covered general oral tablets without corresponding CEP filings for ophthalmic injection-grade PVP, making the raw material ineligible for sterile eye drug formulation registration by the client.
4. Mismatched Batch Traceability & GMP Documentation: Factory factory COA only listed national standard test items, lacking EP Pharmacopoeia-specified test data for residual solvents, heavy metals and microbial limits. No full-chain production batch records or raw material incoming traceability ledgers were available, blocking client on-site audits by EU importers.
Domestic manufacturers specialized solely in production and lacked familiarity with detailed regulatory rules of pharmaceutical authorities across Europe and America; they could only supplement basic product inspection reports without capacity to coordinate cross-border compliance filings. If the client switched raw material suppliers, over 70,000 Euros invested in 3 months of formulation sampling and third-party testing would be fully written off.
HiSiaddi assembled a team of compliance specialists and pharmaceutical excipient technical staff to coordinate three parties: China’s drug authorities, EU compliance institutions and production factories, completing full compliance documentation by four modules.
1. Coordinated manufacturers to add registration for pharmaceutical downstream applications of PVP, entrusted EU local compliance institutions to complete annual SVHC screening reports, focused on verifying DMF (Category 1 reproductive toxic solvent) residual control data from production, and supplemented compliance statements for restricted substances under REACH Annex XVII.
2. Issued bilingual Chinese-English MSDS, reclassified product hazard categories per EU CLP regulations, completed pre-import filing and obtained EU pre-release certificates for imports.
1. Sorted factory GMP production ledgers, clean workshop audit records and batch inspection reports over the past three years, assisted manufacturers in submitting documents to provincial drug authorities for agency processing of the Certificate of Export API to the EU, certifying factory GMP systems aligned with EU pharmaceutical specifications.
2. Submitted documents to Swiss drug authorities simultaneously to complete overseas supplier access filing for domestic PVP, clearing audit barriers for the client’s formulation registration.
1. Assisted manufacturers in updating DMF dossiers in FDA’s new eCTD format, supplemented full toxicology test data for NVP monomers and nitrosamine genotoxic impurities, improved dedicated risk assessment reports for injection-grade raw materials, and completed FDA DMF annual renewal filings.
2. For ophthalmic high-purity PVP, reorganized process research and stability test data, entrusted EDQM-authorized institutions to assist supplementary CEP filing materials for injection-grade grades. Existing CEP-certified grades were temporarily used for oral product customs clearance while CEP approval for new grades advanced in parallel.
1. Guided manufacturers to add EP Pharmacopoeia-mandated testing items including residual solvents, ignition residues and microbial limits, and reissued COA inspection certificates compliant with European and American pharmacopoeia standards.
2. Established full-chain traceability archives for each batch: covering NVP raw material incoming documents → polymerization production records → refining process logs → finished product warehousing & outbound records, realizing one dedicated archive per batch to meet traceability requirements for unannounced inspections by EU drug authorities.
1. Compliance Acceptance: All compliance documents passed pre-review by Swiss drug authorities and EU customs. 10.5 tons of PVP were shipped in six containers from Shanghai Port to Rotterdam Port with smooth customs clearance and zero detention. The client used the raw materials to complete pharmaceutical registration for oral and ophthalmic formulations and launched mass production on schedule.
2. Subsequent Renewal: SandoCare renewed a 13.2-ton annual long-term order the following year, with additional procurement requests for PVP-VA64 copovidone. The group also retained HiSiaddi as a long-term compliance service provider responsible for annual REACH audits, DMF documentation updates and supporting supplier audits.
70,000 Euros of sampling costs were saved from total loss. Domestic PVP procurement costs fell by 29.8% versus BASF imports, and new formulations launched on schedule to capture market share in European ophthalmic pharmaceuticals. Supported by HiSiaddi’s complete compliance supporting system, the client eliminated compliance barriers for subsequent new raw material selection.
Full compliance certifications for EU and US markets were completed. After CEP certification for injection-grade products, the product premium reached 28%. Supported by this benchmark Swiss client compliance case, manufacturers successfully entered supply chains of pharmaceutical enterprises in France and Austria, escaping low-price competition for industrial-grade PVP.
HiSiaddi standardized a full-spectrum compliance service system for pharmaceutical-grade PVP covering REACH registration, drug authority certification agency services, DMF/CEP filing, pharmacopoeia-compliant COA issuance and traceability system construction. It subsequently secured supporting compliance orders from numerous high-end pharmaceutical and cosmeceutical enterprises across Northern Europe and North America.
1. Universal Industry Pain Points: Domestic PVP manufacturers focus primarily on production and lack in-depth understanding of detailed regulatory rules of drug authorities, REACH and pharmacopoeias across Europe and America, only able to provide national standard qualifications. High-end overseas pharmaceutical enterprises face strict supervision from local drug authorities, and raw material compliance documentation directly determines product registration and import customs clearance; information gaps easily lead to suspended orders.
2. Procurement Characteristics of Mid-to-High-End Clients: Compliance qualifications and drug authority access thresholds take priority over unit prices. Low-end industrial-grade PVP does not require rigorous pharmaceutical filing, while mid-to-high-end pharmaceutical grades must satisfy multi-layer compliance requirements of drug authorities across multiple countries.
3. Core Value of HiSiaddi: As a third-party foreign trade compliance service provider, HiSiaddi bridges information gaps between factory production ends and overseas regulatory authorities, pre-judges import compliance risks and provides one-stop agency services for cross-border compliance filings, resolving blind spots in cross-border trade compliance.
Contact HiSiaddi customer service for more inquiries on PVP product compliance issues.
+86-13120989737 
info@hisiaddi.com 
English
